Signant SmartSignals solutions can help researchers improve oncology treatment and therapies. We’ve configured our electronic clinician outcome assessment (eCOA) solution with pre-validated library instruments and oncology-specific features to best support non-small cell lung cancer (NSCLC) research. This helps your team get started faster and significantly reduce costs.

Get details on how Signant helps NSCLC studies:

• Accelerate startup times
• Provide a patient-focused approach
• Simplify the consent process
• Optimize supplies
• Cut costs

Look inside for our NSCLC study experience and therapeutic area experts.